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To understand the relationship between host antigen-presenting cells (APCs) and donor T cells in
initiating graft-versus-host disease (GVHD), we followed the fate of host dendritic cells (DCs) in irradiated C57BL/6 (B6) recipient mice and the interaction of these cells with minor histocompatibility
antigen- (miHA-) mismatched CD8+ T cells from C3H.SW donors. Host CD11c+ DCs were rapidly
activated and aggregated in the T cell areas of the spleen within 6 hours of lethal irradiation. By 5
days after irradiation, <1% of host DCs were detectable, but the activated donor CD8+ T cells had
already undergone as many as seven divisions. Thus, proliferation of donor CD8+ T cells preceded
the disappearance of host DCs. When C3H.SW donor CD8+ T cells were primed in vivo in irradiated
B6 mice or ex vivo by host CD11c+ DCs for 24–36 hours, they were able to proliferate and differentiate into IFN-γ–producing cells in β2-microglobulin–deficient (β2m–/–) B6 recipients and to mediate
acute GVHD in β2m–/– → B6 chimeric mice. These results indicate that, although host DCs disappear
rapidly after allogeneic bone marrow transplantation, they prime donor T cells before their disappearance and play a critical role in triggering donor CD8+ T cell–mediated GVHD.
J. Clin. Invest. 109:1335–1344 (2002). doi:10.1172/JCI200214989.

Introduction
Allogeneic bone marrow transplantation (allo-BMT) has
had a major impact on the treatment of hematologic
malignancies, BM failures, and inherited hematopoietic
disorders, and is finding new application in the treatment of nonhematologic diseases as well. However, graftversus-host disease (GVHD) is still the major complication after allo-BMT, producing multiple-organ damage,
immune deficiency, and infection, such that 10–50% of
patients who receive MHC-matched sibling or unrelated
donor transplants die from complications of the transplant procedure (1, 2). In these patients, GVHD is mediated by donor T cells that recognize minor histocompatibility antigens (miHAs), which are peptides derived from
intracellular proteins that distinguish host from donor
(3–6). Following the presentation of miHAs by antigenpresenting cells (APCs), donor CD4+ and CD8+ T cells are
triggered by miHAs bound to MHC class I and class II
antigens, respectively, to induce acute GVHD (1, 2, 7). In
mouse models of human allo-BMT, both CD4+ and
CD8+ T cells contribute to mediate GVHD (7–9). However, while CD4+ T cells can cause lethal GVHD in only a
few H-2–matched, miHA-mismatched mouse strain
combinations, donor CD8+ T cells can induce lethal
GVHD in most strain combinations (8, 9). This suggests
that CD8+ T cells are the most important T cell subset
contributing to miHA-initiated GVHD.
T cell immune responses are initiated by APCs (10, 11).
While donor-derived and residual host APCs are both
present following allo-BMT, we recently found that host
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APCs are required for CD8+ T cell–dependent GVHD in
a murine model (12). In these studies, infusion of
C3H.SW donor BM and CD8+ T cells failed to induce
acute GVHD in miHA-mismatched β2-microglobulin
gene–deficient (β2m–/–) → C57BL/6 (B6) chimeric mice,
a model in which hematopoietic cells of B6 mice, including APCs, were replaced by β2m–/– mouse–derived BM
cells (12). The failure of these β2m–/– → B6 chimeric
recipients of C3H.SW donor BM and CD8+ T cells to
develop acute GVHD indicates that donor-derived APCs
are insufficient to induce acute GVHD, and therefore
that T cell–host APC interactions are essential for triggering the induction of acute GVHD.
Several cell types can function as APCs, including
dendritic cells (DCs), macrophages, B cells, and nonhematopoietic cells (10, 11, 13, 14). However, it remains
unclear how host APCs initiate donor CD8+ T
cell–mediated acute GVHD in this miHA-mismatched
murine model. Since DCs are the most potent APCs
specialized for the initiation of primary T cell immunity (10, 11), understanding the relationship between DC
activation, T cell–DC interaction, and T cell expansion
following allo-BMT will be helpful for further elucidating the pathophysiology of acute GVHD at the cellular and molecular levels.
In this study, we explored the fate of host DCs and
their role in activating donor CD8+ T cells following
total body irradiation (TBI) and allo-BMT. The results
show that the activation of host DCs and donor T cells
occur extremely early in transplant recipients following
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irradiation and cell transplantation. Host DCs are able
to activate donor CD8+ T cells within 24 hours, before
they themselves disappear as the result of allo-BMT
conditioning. These findings point to the immediate
allo-BMT period as the key window for the induction,
and therefore possible prevention, of acute GVHD.

Methods
Mice. B6 (H-2b, CD45.2+) or B6/SJL (H-2b, CD45.1+)
recipient mice, miHA-mismatched C3H.SW (H-2b,
CD45.2+, and Ly9.1+) donor mice, β2m–/– B6 mice (H-2b,
CD45.2+), and BALB/c mice (H-2d) were purchased
from The Jackson Laboratory (Bar Harbor, Maine,
USA) and maintained in sterile conditions. From 2 days
before irradiation until 3 weeks after transplant, the
drinking water of BMT recipients was supplemented
with neomycin sulfate and polymyxin B (Sigma
Aldrich, St. Louis, Missouri, USA).
Ab’s. The primary Ab’s used for cell immunofluorescent
and immunohistochemical staining and cell separation,
including anti-CD3 (clone 145-2C11), anti-CD4 (clone
GK1.5), anti-CD8 (clone RM4-5), biotinylated anti–mouse
IFN-γ, biotinylated anti-CD11b (clone M1/70), biotinylated anti-CD11c (clone HL3), biotinylated anti-NK1.1,
and biotinylated anti-B220, were obtained from Pharmingen (San Diego, California, USA). FITC–anti-CD11a,
FITC–anti-CD40, FITC–anti-CD86, FITC–anti-Ia, FITC,
phycoerythrin-conjugated (PE-conjugated) streptavidin,
PE–anti-CD25, PE–anti-CD62L, PE–anti-CD69, PE–antiCD11c, Cychrome–anti-CD8, and Cychrome-streptavidin
were also obtained from Pharmingen. All anti-CD4, antiCD8, anti-B220, anti-CD11b, and anti-CD11c Ab’s conjugated with microbeads and the streptavidin conjugated
with microbeads were purchased from Miltenyi Biotech
(Auburn, California, USA).
Cell preparations. Donor BM cells were prepared from
C3H.SW mice as previously described (12). T cell–depleted BM (T–BM) cells were further prepared using antiCD4 and anti-CD8 Ab’s conjugated with magnetic
microbeads. Donor CD8+ T cells were purified from
C3H.SW mice by one of two protocols. In the first, CD8+
T cells were positively selected from spleens and lymph
nodes of C3H.SW mice with anti-CD8+ Ab conjugated
with magnetic microbeads. Alternatively, CD8+ T cells
were negatively selected by depletion of CD11b, NK1.1,
B220, and CD4 cells using magnetic cell sorting (MiniMACS; Miltenyi Biotech) (12, 15). Since murine DCs
express CD8 antigen (16), CD11c+ cells were also completely removed using anti-CD11c Ab conjugated with
microbeads before purifying donor CD8+ T cells. The
purity of isolated donor CD8+ T cells was always more
than 95%, as reanalyzed by flow cytometry.
CD11c+ DCs were isolated from B6 or C3H.SW splenocytes by magnetic cell sorting as previously described
(15). The purity of isolated CD11c+ DCs was more than
90% as analyzed by flow cytometry. In some experiments,
purified DCs were cultured ex vivo in Iscove’s modified
Dulbecco’s medium containing 10% FCS and GM-CSF
(R&D Systems Inc., Minneapolis, Minnesota, USA) in
1336
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96-well plates at a cell concentration of 2 × 105 cells/well.
The supernatants were collected at 48 hours for assessing the secretion of IL-12 as previously described (15).
Carboxyl fluorescein succinimidyl ester labeling. C3H.SW
CD8+ T cells were resuspended at a concentration of
1 × 107 cells/ml in 2.5% FBS in PBS. Carboxyl fluorescein succinimidyl ester (CFSE; Molecular Probes,
Eugene, Oregon, USA) was added to a final concentration of 5 µM. Labeling was quenched with ice-cold PBS
after 15 minutes of incubation at 37°C. Cells were
washed twice in PBS and resuspended in PBS for transplantation in vivo or in medium for in vitro culture.
Isolation of hepatic lymphocytes. Hepatic lymphocytes
were isolated as previously described (17). Briefly, livers
from B6 mice were minced and suspended in PBS containing 1 mM EDTA. Percoll was added to the cell suspension (Amersham Pharmacia Biotech, Piscataway,
New Jersey, USA) to a final concentration of 33%. After
centrifugation for 30 minutes at room temperature,
hepatic lymphocytes were collected from the bottom
and contaminating red blood cells were lysed.
BMT and CD8+ T cell transplantation. Mice underwent
allo-BMT as previously described (12). Briefly, normal B6
and β2m–/– B6 recipients received 9.5 Gy TBI administered in two treatments from a 137Cs source. C3H.SW
CD8+ T cells (2 × 106 to 3 × 106), with or without 7 × 106
C3H.SW T–BM cells, were transplanted into the recipients by tail vein injection (five to six mice per group per
experiment) immediately after irradiation. Recipient
mice were weighed twice weekly and were monitored for
acute GVHD and for survival. The clinical grading for
the cutaneous inflammation of GVHD was followed
according to established criteria (2, 18). In some experiments, β2m–/– → B6 chimeric mice were irradiated with
7.5 Gy and used as recipients. To create β2m–/– → B6
chimeric mice, 1 × 107 BM cells derived from β2m–/– B6
mice were transplanted into lethally irradiated B6 mice
as previously described (12). These β2m–/– → B6 chimeric
mice were maintained for 4 months before subsequent
use as recipients of allo-BMT. By this time, more than
96% of hematopoietic cells from BM, lymph node, and
spleen were negative for MHC class I antigens (12).
Cytokine assays. IL-12 (p40) in the serum and supernatants of DC cultures was measured by ELISA according to the manufacturer’s instructions (BioSource
International, Camarillo, California, USA). Intracellular IFN-γ in donor T cells was performed as previously
described with slight modification (19). Briefly, splenocytes and hepatic lymphocytes were cocultured with
MC57SV cells (H-2Db, a cell line derived from B6 mice)
irradiated with 30 Gy in the Nunc MicroWell plate precoated with anti-CD3 Ab for 16 hours. GolgiStop
(Pharmingen) was added for the last 6 hours of culture.
Cells were collected and stained with Cychrome–antiCD8 Ab with or without FITC–anti-CD11a. After fixation and permeabilization using the Cytofix/Cytoperm
Plus Kit (Pharmingen), cells were stained with biotinylated mouse anti–IFN-γ followed by PE-conjugated
streptavidin, and then analyzed by flow cytometry.
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Mixed lymphocyte reaction. After irradiation with 15 Gy,
the indicated splenic DCs from B6 mice were cocultured with purified BALB/c CD4+ T cells in 96-well
MicroWell tissue-culture plates (Nunc A/S, Roskilde,
Denmark). After incubation for 4 days, cell proliferation was determined using the 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma
Aldrich) assay as previously described (20).
Flow cytometry analysis. Immunofluorescence analyses
were performed as previously described (21). In twocolor analyses, splenic DCs were stained with FITC-conjugated anti-CD86, anti-Ia, and PE-conjugated antiCD11c Ab’s. In other experiments, CFSE-labeled CD8+
T cells were further stained with Cychrome-conjugated
anti-CD8 coupled with PE-conjugated anti-CD25, antiCD69, and anti-CD62L Ab’s. Cells were analyzed by
FACScan (Becton Dickinson Immunocytometry Systems, Mansfield, Massachusetts, USA) with instrument
compensation set in each experiment using single
and/or two-color stained isotype control samples.
Pathologic examination of tissues. Mice were sacrificed,
and specimens of liver, skin, and intestine were taken
for histopathologic analysis. All samples were placed
in 10% neutral buffered formalin (Sigma Aldrich),

embedded in paraffin, sectioned, and stained with
hematoxylin and eosin for histopathologic assessment
of acute GVHD (2, 22).
Immunohistochemical and fluorescent staining of tissues. For
immunofluorescence detection of CD11c antigen,
recipient spleens were frozen in O.C.T. embedding
medium (Sakura Finetek USA Inc., Torrance, California,
USA). Six-micrometer frozen sections were cut, airdried, fixed in acetone, and rehydrated in PBS. Spleen
sections were incubated with biotinylated hamster
anti–mouse CD11c Ab (Pharmingen) and revealed with
PE-conjugated streptavidin (Vector Laboratories,
Burlingame, California, USA), respectively. Nonspecific
binding of biotin and avidin was blocked by addition of
excess avidin and biotin using the Blocking Kit from
Vector Laboratories. Isotype-matched rat IgG (Pharmingen) was used as a negative control. After staining, the
slides were coverslipped using antifade mounting medium (Vectashield, H-1200; Vector Laboratories) and
observed under a fluorescent microscope (Nikon
Microphot-FXA; Nikon Inc., Melville, New York, USA).
Immunohistochemical staining of spleen, liver, and
skin was performed as previously described (15, 17). The
sections of liver and skin were stained with rat anti-CD8

Figure 1
Development of acute GVHD in B6 recipients transplanted with C3H.SW T–BM cells and CD8+ T cells. (a) Recipient weight loss and (b)
actuarial survival rate. Recipients were conditioned with 9.5 Gy TBI and then administered 7 × 106 C3H.SW T–BM cells alone (n = 12; diamonds) or along with 3 × 106 C3H.SW CD8+ T cells (n = 17; squares). Data are derived from three separate experiments. (c) Infiltration of
lymphocytes and CD8+ T cells in liver and skin (arrows) during GVHD. Livers and skin were harvested from mice and sectioned for histologic staining with hematoxylin and eosin (HE) and immunohistochemical staining with anti-CD8 Ab as described in Methods. Magnification:
left, ×100; right, ×200. (d) Intracellular IFN-γ expression in hepatic CD8+ T lymphocytes. Hepatic lymphocytes were isolated from mice and
restimulated in vitro in the presence or absence of anti-CD3 Ab plus MC57SV cells (H-2Db) irradiated with 30 Gy for 16 hours. Lymphocytes
were then labeled with anti-CD8 and anti-CD11a Ab’s, fixed, permeabilized, and labeled with anti–IFN-γ Ab. The expression of intracellular
IFN-γ in CD8+ T cells was quantitated by flow cytometry. Dot plots shown are from IFN-γ and CD11a labeling of gated CD8+ T cells.
The Journal of Clinical Investigation
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Figure 2
Elimination of CD11c+ DCs in the spleens of irradiated mice. Spleen
cells were isolated from lethally irradiated B6 mice 6 hours, 24 hours,
and 5 days after TBI with or without transplantation of C3H.SW
CD8+ T cells, and CD11c+ DCs were enumerated by flow cytometry.
(a) Percentage and (b) absolute number of CD11c+ DCs in the
spleens of B6 mice injected with PBS, irradiated B6 mice injected with
PBS, or irradiated B6 mice infused with C3H.SW CD8+ T cells. Data
are representative of three experiments.

Ab (Pharmingen) followed by horseradish peroxidase–conjugated (HRP-conjugated) goat anti–rat
IgG(Fab′)2 (Vector Laboratories) and were developed
with a diaminobenzidine (DAB) substrate kit (Vector
Laboratories). The spleen sections were stained with
biotinylated hamster anti–mouse CD11c Ab followed
by HRP-conjugated streptavidin and developed with
DAB substrate (brown). After inactivating HRP using
3% H2O2-PBS, these spleen sections were stained with
rat anti–mouse CD4 Ab followed by staining with HRPconjugated goat anti–rat IgG(Fab′)2. The sections were
developed with DAB-Ni substrate (gray-black) (Vector
Laboratories). Isotype-matched rat IgG (Pharmingen)
was used as a negative control.
Statistical analysis. Survival data were analyzed by life
table methods using the Mantel-Peto-Cox summary of
χ2. P values smaller than 0.05 were considered significant.

Results
C3H.SW mouse–derived donor CD8+ T cells mediate GVHD in
B6 recipients. In previous studies (12), donor CD8+ T cells
used for the induction of acute GVHD contained
CD8+CD11c+ lymphoid DCs that could partially crosspresent host antigens to activate CD8+ T cells (10, 23,
24). To investigate whether donor CD8+ T cells depleted
of CD8+CD11c+ lymphoid DCs can induce lethal
GVHD, we purified donor CD8+ T cells from C3H.SW
mice by sequentially depleting CD11c+, CD11b+, CD4+,
B220+, and NK1.1+ cells using magnetic cell sorting.
Lethally irradiated B6 mice that received donor CD8+
1338
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T cells plus T–BM developed significant acute GVHD, as
manifested by weight loss (Figure 1a), cutaneous inflammation (12 of 17 recipients), periportal infiltration of
inflammatory cells, accumulation of CD8+ T cells in the
liver and skin (Figure 1c), and death (7 of 17 recipients)
(Figure 1b). Intracellular cytokine staining demonstrated that donor CD8+ T cells isolated from the recipient
livers at 28 days after BMT were activated and secreted
increased levels of IFN-γ (Figure 1d). In contrast, recipients infused with donor T–BM alone did not show any
sign of GVHD (Figure 1). Thus, C3H.SW mouse–derived
CD8+ T cells from which donor CD8+CD11c+ DCs are
depleted can induce acute GVHD in irradiated B6 recipients by responding to the residual host APCs.
Irradiation of B6 recipients induces the activation, maturation,
and rapid elimination of host DCs. Since DCs are the APCs
specialized for eliciting primary T cell responses (10),
determining the fate of host DCs following TBI may illuminate how host APCs initiate donor CD8+ T cell–mediated GVHD. We first examined the fate of host DCs in
the spleens of B6 mice following lethal TBI. Flow cytometry analysis showed that 6–24 hours after TBI, the density of host CD11c+ DCs increased substantially in recipient spleens (Figure 2a). However, TBI reduced the overall
cellularity of recipient spleens by 73.7% and 87.4% by 6
hours and 24 hours, respectively. The absolute number of
host CD11c+ DCs thus declined significantly by 6 hours
following TBI, and by day 5 more than 99.0% of host DCs
in the spleen were eliminated (Figure 2b). Infusion of
donor CD8+ T cells immediately after TBI further
increased the percentage of splenic CD11c+ DCs in TBI
recipients at 6 and 24 hours, but did not rescue the overall loss of host CD11c+ DCs during this 5-day period
(Figure 2, a and b). We likewise observed that DCs were
diminished in the peripheral lymph nodes, blood, liver,
and skin of recipients at 24 hours and were undetectable
in these tissues by 5 days after irradiation (data not
shown). The rapid elimination of host DCs during the
first few days following TBI was surprising, since acute
GVHD was not clinically and pathologically detected in
the recipients until 1–2 weeks after allo-BMT (Figure 1).
It is believed that activation of naive T cells depends on
the maturation state of DCs in vivo (10). Several experiments were performed to examine whether host DCs
might be functionally activated following irradiation but
prior to their disappearance. As shown in Figure 3a,
splenic DCs from irradiated mice expressed increased
numbers of Ia and CD86 as early as 6 hours after irradiation; this increase was not related to whether or not T–BM
and/or T cells were infused (Figure 3b). The increased
expression of CD86 persisted as long as 24 hours, whereas Ia was downregulated at 24 hours (Figure 3a). When
splenic DCs were isolated and cultured ex vivo for an
additional 48 hours, DCs isolated from irradiated B6
mice at 6 hours, but not those isolated at 24 hours following TBI, produced significantly higher levels of IL-12
than the cells from nonirradiated mice did, consistent
with the increased levels of serum IL-12 detected in these
irradiated mice (Figure 3c). Moreover, DCs isolated from
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Figure 3
Irradiation upregulates the expression of antigen-presenting and costimulatory molecules on DCs. Splenic DCs were isolated from (a) irradiated
mice at 6 hours and 24 hours after irradiation or (b) irradiated mice infused with donor CD8+ T cells or donor CD8+ T cells + T–BM cells. These
purified DCs were double stained with anti-CD11c Ab coupled with anti-Ia Ab or anti-CD86 Ab as described in Methods. The expression of Ia
and CD86 antigens on the CD11c+ cell population was analyzed by flow cytometry. Isotype-matched IgG was used as control. (c) IL-12 in serum
from nonirradiated and irradiated B6 mice at 6 hours, 24 hours, and 5 days following TBI or in the supernatants of cultured host DCs was examined by ELISA. Host splenic DCs were separately purified from the spleen of B6 mice at 6 and 24 hours following TBI or from nonirradiated mice
as described in Methods. The supernatants were collected from the cultures of DCs at 48 hours. *P < 0.05 compared with samples from nonirradiated mice or irradiated mice at 24 hours and 5 days after TBI. (d) Host DCs were isolated from nonirradiated B6 mice (diamonds) and from
B6 mice at 6 hours (triangles) and 24 hours (circles) after irradiation. These cells were cocultured with BALB/c mouse–derived CD4+ T cells to
examine their capacity to stimulate an allogeneic mixed lymphocyte reaction. Activated DCs that were induced by culturing naive B6 DCs in the
presence of GM-CSF + TNF-α for 48 hours were used as positive control (squares). One representative experiment of three is shown.

irradiated B6 mice at 6 hours following TBI showed
greater capacity than did the cells from nonirradiated
naive B6 mice to stimulate the allogeneic mixed lymphocyte reaction (Figure 3d). Taken together, these results
indicate that the BMT-preparative irradiation rapidly
induced the functional activation of host DCs prior to
their disappearance.
Host DCs intimately interact with infused donor naive CD8+ T
cells in vivo. Direct contact between host APCs and resting
donor T cells is essential for initiating primary immune
responses (10, 25). Therefore, if host DCs are essential to
allogeneic donor T cell activation, direct proximity of
DCs to T cells should be detectable before the disappearance of host DCs following irradiation. To test this
hypothesis, C3H.SW CD8+ T cells were labeled with the
fluorescent dye CFSE and transplanted into lethally irradiated B6 recipients. Two-color immunohistochemical
staining of spleen sections with anti-CD11c and antiCD4 Ab’s revealed that CD11c+ DCs were significantly
concentrated in the T cell areas of the spleens from B6
recipients at 6 hours following TBI and cell transplantation (Figure 4a). Fluorescence microscopy showed that
The Journal of Clinical Investigation
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donor CFSE-CD8+ T cells were readily detected in the
spleens by 6 hours following infusion. These CFSE-CD8+
T cells were seen in direct proximity to host DCs in situ
(Figure 4b). Flow cytometry analysis showed that about
5–10% of all infused donor CFSE-CD8+ T cells were
recruited into the spleen by 6–24 hours following transplantation, and this number increased five- to tenfold by
day 5 (Figure 4c). In contrast, CFSE-CD8+ T cells were not
detected in the skin and were only sparsely detected in the
liver (less than 0.3% of all hepatic leukocytes) at 24 hours
after infusion (data not shown). Thus, transplanted
donor CD8+ T cells form an intimate interaction with
preterminal host DCs in the T cell areas of the spleen
where primary T cell response is initiated.
Allogeneic donor T cells rapidly upregulate activation antigens
and proliferate shortly after infusion. We next assessed the early
responsiveness of donor CD8+ T cells in the recipients following TBI. Six hours after transplantation of donor
C3H.SW CD8+ T cells (CD45.2+) into lethally irradiated
B6/SJL recipients (CD45.1+), flow cytometry analysis
demonstrated increased expression of the activation antigen CD25 on about 90% of donor T cells recovered from
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Figure 4
Donor CD8+ T cells are rapidly recruited to the T cell areas of recipient spleens, in direct proximity to host CD11c+ DCs. CFSE-labeled CD8+ T cells
(2 × 106) derived from C3H.SW mice (CD45.2+) were intravenously injected into lethally irradiated B6/SJL mice (CD45.1+). (a) Aggregation of
CD11c+ DCs in the T cell areas of the spleens of irradiated mice. Cryosections of spleen harvested from lethally irradiated B6 mice 6 hours after
TBI were immunostained with anti-CD11c Ab (brown) and anti-CD4 Ab (gray-black). Magnification: top row, ×100; bottom row, ×400. Data
are representative of three experiments. (b) Spleens were taken from B6 mice 6 hours after PBS injection and from irradiated B6 mice 6 hours after
infusion of CFSE-labeled C3H.SW CD8+ T cells (green) and cryosectioned for immunofluorescent staining with anti-CD11c Ab (red). Magnification, ×100. (c) Splenocytes were prepared and counted at the indicated timepoints. Cells were sequentially labeled with Cychrome-conjugated
anti-CD8 Ab coupled with biotinylated anti-CD45.2 and streptavidin-conjugated PE. The percentage of CD8+CD45.2+ cells was obtained by flow
cytometry analysis. The recruitment rate (percentage) of donor CD8+ T cells in spleen was calculated by dividing the absolute number of donor
CD8+ T cells recovered from the spleens of irradiated recipient mice by the total number of intravenously injected donor CD8+ T cells.

recipient spleens (Figure 5a). Similarly, the expression of
CD69 antigen on these donor CD8+ T cells was increased
while that of CD62L antigen was decreased (data not
shown), indicating rapid activation of allogeneic T cells in
vivo (2). At 24 hours after transplantation, about 2.4% of
transplanted CFSE-labeled donor C3H.SW CD8+ T cells
had divided. Donor T cell proliferation amplified extensively over the next several days, such that as many as seven
divisions per T cell were detected by day 5, whether or not
donor T–BM cells were included in the infusion (Figure
5b). These results suggest that allogeneic CD8+ T cells are
activated before the elimination of host DCs.
To further examine the relationship between proliferation of donor CD8+ T cells and the disappearance of host
DCs, C3H.SW CFSE-CD8+ T cells were transplanted into
B6 recipients at 0, 24, 48, 72, and 120 hours following
TBI. Five days after the cell transplantation, activation
and expansion of donor CD8+ T cells were analyzed by
flow cytometry. Compared with the transplantation of
donor T cells immediately after TBI, delayed infusion of
these donor CFSE-CD8+ T cells into B6 recipients at
24–120 hours after TBI significantly inhibited their division and proliferation in the recipients (Figure 6a). The
absolute number of donor CD8+ T cells that underwent
more than seven divisions in recipient spleen were
1340
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markedly decreased from 3.0 × 105 ± 0.4 × 105 at 0 hours
to 1.06 × 105 ± 0.5 × 105 at 24 hours, 1.43 × 105 ± 0.33 ×
105 at 48 hours, 0.57 × 105 ± 0.1 × 105 at 72 hours, and
0.68 × 105 ± 0.04 × 105 at 120 hours after TBI. Identically, when β2m–/– B6 mice were substituted for B6 recipient
mice, donor CD8+ T cell division was remarkably inhibited, largely limited to one or two divisions by day 5 (Figure 6b, lower panel). It is not clear whether this limited
allogeneic T cell proliferation in β2m–/– B6 recipients
might be induced by recognition of free MHC class I
chains by donor CD8+ T cells (26) or whether memory
CD8+ T cells retain their functional characteristics and
proliferate in the absence of MHC class I (27). Nevertheless, this reduction in cell division resulted in a markedly
reduced (fivefold) expansion of donor CD8+ T cells in
β2m–/– B6 mice by day 5 after transplantation (Figure 6c).
Thus, activation and proliferation of donor CD8+ T cells
are closely associated with the disappearance of host DCs
in vivo, which requires the presence of functional MHC
class I molecules on the host APCs.
Early priming of donor CD8+ T cells by host APCs is sufficient
to trigger allogeneic T cells to mediate lethal GVHD in β2m–/– →
B6 chimeric mice. Since host DCs were eliminated in the
spleens of mice during the first few days after irradiation
in parallel with donor T cell proliferation, we asked
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whether the early exposure of donor T cells to activated,
preterminal DCs was sufficient to trigger acute GVHD.
To test this hypothesis, CFSE-labeled C3H.SW (CD45.2+)
CD8+ T cells were infused into lethally irradiated B6/SJL
recipients (CD45.1+). Twenty-four to 36 hours later, recipient mice were sacrificed and C3H.SW CD8+ T cells were
isolated from recipient spleens and lymph nodes by positive selection based on the expression of CD45.2 antigen.
The purity of separated CD8+CD45.2+ T cells was more
than 96%, and contamination of CD11c+ cells was undetectable by flow cytometry. These in vivo primed CD8+ T
cells were then adoptively transferred into lethally irradiated β2m–/– B6 recipients, and the proliferation and differentiation of these T cells were examined 6 days after
adoptive transfer. As shown in Figure 7a, these in vivo
primed C3H.SW CD8+ T cells spontaneously underwent
at least seven divisions and secreted high levels of IFN-γ
in the secondary β2m–/– B6 recipient mice. In contrast,
unprimed C3H.SW CD8+ T cells were unable to extensively divide and differentiate into IFN-γ–producing cells
in β2m–/– recipients (Figure 7a).
To further investigate whether short-lived but activated host CD11c+ DCs might be responsible for priming
donor T cells in vivo, CFSE-labeled C3H.SW CD8+ T cells
(CD45.2+) were cultured ex vivo with CD11c+ DCs that
were isolated from spleens and lymph nodes of B6/SJL
(CD45.1+) mice 6 hours after lethal irradiation. Twentyfour hours later, these primed C3H.SW CD8+ T cells were
magnetically sorted from the cultures to completely

remove host DCs and adoptively transferred into the irradiated β2m–/– B6 recipients and β2m–/– → B6 chimeric
mice. As shown in Figure 7b and Table 1, these C3H.SW
CD8+ T cells primed ex vivo by host CD11c+ DCs underwent as many as seven divisions and differentiated into
effectors secreting high levels of IFN-γ following adoptive
transfer into β2m–/– mice. In contrast, priming of C3H.SW
CD8+ T cells with syngeneic C3H.SW CD11c+ DCs or
medium alone failed to induce the proliferation and
functional differentiation of these T cells into effectors
secreting IFN-γ under the same conditions. (Table 1).
Finally, six of seven β2m–/– B6 → B6 BM chimeric recipients that received C3H.SW T–BM plus CD8+ T cells that
were primed ex vivo by host CD11c+ DCs developed
severe GVHD by day 30 and died from lethal GVHD (Figure 7c). In contrast, only one of five β2m–/– → B6 BM
chimeric recipients transplanted with unprimed donor
CD8+ T cells showed any signs of GVHD, with a delayed
onset (Figure 7c; P < 0.05 compared with those recipients
accepting host DC–primed donor CD8+ T cells), consistent with previous observations (12). Thus, exposure of
donor CD8+ T cells to host DCs for 24 hours was sufficient to trigger the proliferation and differentiation of
CD8+ T cells and could induce acute GVHD.

Discussion
The studies in this model of MHC-matched, miHA-mismatched allo-BMT demonstrate that preparative TBI for
allo-BMT can rapidly induce the functional maturation

Figure 5
Activation of donor naive CD8+ T cells upon intravenous injection into lethally irradiated B6 recipients. (a) Naive CD8+CD45.2+ C3H.SW T cells
(2 × 106) were intravenously injected into lethally irradiated B6/SJL recipients (CD45.1+). At the indicated timepoints, splenocytes were prepared
from these mice and tricolor-stained with anti-CD8, anti-CD45.2, and anti-CD25 Ab’s, which were separately revealed with FITC, Cychrome, and
PE. After gating on CD45.2+ donor–derived T cells, the expression of CD25 on CD8+ T cells was analyzed by flow cytometry. (b) CFSE-labeled
CD8+ T cells (2 × 106) from C3H.SW donor mice (CD45.2) were transferred with or without mixed donor T–BM cells into lethally irradiated B6/SJL
recipient mice (CD45.1). At the indicated timepoints after transplantation, splenocytes were prepared from these mice, stained with anti-CD8 Ab
conjugated with Cychrome, and then sequentially labeled with biotinylated anti-CD45.2 and streptavidin-conjugated PE. The division of donor
CD8+ T cells in vivo was analyzed by flow cytometry by gating on CD8+CD45.2+ T cells. One representative experiment of three is shown.
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Figure 6
The activation and proliferation of allogeneic CD8+ T cells depend on
the presence of host DCs and require MHC class I expression on host
cells. (a) CFSE-labeled CD8+ T cells (2 × 106) from C3H.SW mice
(CD45.2+) were transplanted into irradiated B6 recipients (CD45.1+)
at the indicated timepoints after TBI. Five days later, splenocytes were
prepared from these mice for flow cytometry analysis as described in
Figure 5b legend. (b) C3H.SW CFSE-CD8+CD45.2+ T cells (2 × 106)
were intravenously transferred into lethally irradiated β2m–/– mice or
congenic B6/SJL (CD45.1+) recipients. Splenocytes were prepared from
these mice, and the division of donor CD8+ T cells was analyzed by flow
cytometry. The absolute number (c) of C3H.SW CD8+ T cells in the
spleens of recipients 5 days after transplantation was calculated based
on the flow cytometry analysis. Data shown derive from five independent experiments. One representative experiment of three is shown.

of host DCs, which trigger the committed differentiation of allogeneic CD8+ T cells. DCs are sentinel APCs
distributed throughout tissues as an immature form
(10). In response to various stimuli (including infectious
agents, inflammatory cytokines, and endogenous signals
released by cells undergoing stress, damage, and necrosis), immature DCs can be activated in vivo (10, 15, 28,
29). We found that preparative irradiation resulted in
significantly increased serum levels of IL-12 and functional activation of host DCs within as little as 6 hours.
Since we found that freshly isolated splenic DCs underwent spontaneous maturation upon in vitro culture
(data not shown), consistent with others’ observations
(16, 28), it was difficult to evaluate whether ex vivo irradiation might directly affect the maturation of freshly
isolated host DCs. Previous studies indicate that preparative irradiation for BMT results in the damage of host
tissues and release of inflammatory cytokines such as
IL-1 and TNF-α (30–35), which are closely related to the
increased risk of lethal GVHD in animal models as well
as in human BMT (1, 30, 33, 36). Accordingly, the early
released inflammatory cytokines and damaged tissues
undergoing stress and necrotic death may play a critical
1342
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role in inducing the rapid activation of host DCs in
lethally irradiated recipients. Thus, preventing the activation of host DCs induced by an intensive myeloablative regimen and other risk factors, particularly in the
first few days following clinical BMT, might be helpful
for reducing the incidence of acute GVHD.
We found that TBI significantly diminished the number of host splenic DCs in the recipients soon after irradiation and eliminated more than 99% of them by day 5.
Such elimination of host DCs was not related to the redistribution of host DCs in vivo, since there were not signs of
DC accumulation in other tissues of irradiated recipients.
Several previous studies have demonstrated that systemic
inflammation can induce the disappearance of activated
DCs within 24 to 48 hours in the T cell areas of spleen (10,
15, 37). After terminal maturation and interaction with
lymphocytes, DCs die in situ in the secondary lymphoid
tissues by apoptosis (10, 29, 37). Thus, preparative irradiation, through its simultaneous induction of DC maturation and its direct toxicity to DC precursor cells, results
in the elimination of host DCs in the recipients.
Accumulating evidence points to the fact that the
early interaction between allogeneic T cells and residual
host APCs immediately after allo-BMT is critical for eliciting acute GVHD (12, 38–42). Compared with the
transplantation of donor lymphocytes on the day of
BMT, delayed lymphocyte infusion of allogeneic T cells
into the recipient mice between day 7 and day 21 after
BMT results in decreased generation of cytolytic and
helper T cells (42) and a reduced incidence of lethal
GVHD (38–42). Although it has been suggested that the
presence of fewer host APCs in the recipients after alloBMT might account for decreased severity of GVHD in
these delayed lymphocyte infusion models (40), the
kinetic window in which host APCs function to elicit
acute GVHD has been uncertain. We observed that the
elimination of host DCs by TBI did not prevent the activation and proliferation of allogeneic CD8+ T cells that
were transplanted into the recipients immediately after
irradiation. In contrast, delayed infusion of donor CD8+
T cells into the B6 recipients between 3 days and 5 days
after TBI substantially inhibited the activation and
rapid proliferation of these allogeneic T cells in vivo. We
conclude that activated host DCs trigger the activation
and proliferation of allogeneic CD8+ T cells prior to
their decay and disappearance. Delayed infusion of
donor T cells may result in a significant reduction in the
chance for donor T cells to encounter activated host
DCs in the recipients, thereby blunting the effect of host
DCs on triggering the activation and functional differentiation of host-specific donor CD8+ T cells.
Our experiments address the issue of the duration of
interaction between host DCs and donor T cells required
to trigger allogeneic CD8+ T cells to differentiate into
GVHD effectors. When C3H.SW CD8+ T cells were
primed ex vivo for 24 hours by activated B6 CD11c+ DCs
and adoptively transferred into β2m–/– → B6 chimeric
mice, the sensitized allogeneic CD8+ T cells could lead to
the lethal GVHD in these chimeric recipients by 30 days.
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Figure 7
Brief priming by host DCs triggers the committed differentiation of donor naive CD8+ T cells into effectors. (a) Naive C3H.SW CFSE-CD8+ T cells
were intravenously injected into lethally irradiated B6/SJL (CD45.1+) mice. After 24 to 36 hours, these primed C3H.SW CFSE-CD8+ T cells were
then purified and adoptively transferred into secondary irradiated β2m–/– recipient mice. Six days later, cells from the spleens and lymph nodes of
secondary recipients were cultured in the presence or absence of CD3 Ab plus MC57SV cells irradiated with 30 Gy for measuring IFN-γ production as described in Methods. Dot plots shown represent IFN-γ and CFSE intensity measured in gated CD8+ T cells. Naive unprimed C3H.SW
CFSE-CD8+ T cells were injected into lethally irradiated B6/SJL mice (CD45.1+) and β2m–/– mice as control. (b) C3H.SW CFSE-CD8+ T cells were
stimulated ex vivo by host CD11c+ DCs for 24 hours, recovered, sorted, and adoptively transferred into irradiated β2m–/– mice. Six days later, cells
from spleens and lymph nodes were separated from the secondary recipients and stained with anti-CD8 Ab for measuring donor CD8+ T cell divisions. These cells were also cultured for 16 hours as described in a, to measure IFN-γ secretion. (c) Survival rate of β2m–/– B6 → B6 BM chimeric
mice that received either C3H.SW T–BM alone, C3H.SW T–BM + C3H.SW CD8+ T cells, or C3H.SW T–BM + C3H.SW CD8+ T cells that were
primed ex vivo by B6 CD11c+ DCs. Representative results from two independent experiments are shown.

These results indicate that host DCs can prime donor
CD8+ T cells within 24 hours. Using engineered fibroblast
APCs expressing B7.1 and pSigOVA(257-264), van Stipdonk et al. recently showed that priming naive OT-I CD8+
T cells for 2 hours in an in vitro culture was sufficient for
inducing rapid division and CTL activity of these OT-I T
cells in the absence of any further antigenic stimulation
(43). Two other in vivo studies based on animal models
showed that either bacterial or malaria antigen–specific
transgenic naive CD8+ T cells can become committed
to differentiation into protective effectors secreting
high levels of IFN-γ after initial antigen encounter
in vivo for 24 hours (44). Our present results support
these conclusions and extend this to cellular allogeneic
miHAs in an in vivo murine GVHD model analogous to
human clinical BMT. Thus, antigen stimulation is required only briefly immediately after BMT for priming

donor T cells to trigger their proliferation and committed
differentiation into functional effectors of GVHD.
Previous studies have demonstrated that both professional and nonprofessional APCs may support alloresponses (10, 11, 13, 45). Although the present study
establishes the critical effect of host DCs at a very early
stage following allo-BMT on initiating allogeneic CD8+
T cell–mediated acute GVHD in vivo, we do not rule out
the role of other host APCs such as macrophages, B cells,
and some semiprofessional APCs in vivo in presenting
miHAs to activate donor CD8+ T cells. Moreover, we have
previously observed the presence of a small number of
radio-resistant host APCs in recipients 4 months after
allo-BMT. Thus, it is possible that maturation of primed
CD8+ T cells into GVHD effectors following adoptive
transfer into β2m–/– → B6 chimeric mice could have been
aided by the few radio-resistant host APCs. This raises

Table 1
The dependence of CD8+ T cell activation and division on allogeneic DCs
Ex vivo priming
Medium
C3H.SW CD11c+ DCs
B6 CD11c+ DCs

CD8+IFN-γ+ T cells (%)

CD8+ T cells undergoing more than five divisions (%)

0.605 ± 0.08
0.505 ± 0.15
8.03 ± 3.56A

2.9 ± 0.33
3.9 ± 0.5
18.9 ± 3.6A

Values are presented as mean ± SD for three animals in each group. C3H.SW CFSE-CD8+ T cells were incubated in medium alone or stimulated with host B6
CD11c+ DCs or C3H.SW CD11c+ DCs in vitro for 24 hours, then recovered, sorted and adoptively transferred into irradiated β2m–/– B6 mice. Six days later,
cells from spleen and lymph nodes were separated from the secondary recipients and stained with anti-CD8 and anti–IFN-γ Ab’s to measure IFN-γ secretion
by CD8+ T cells. ASignificant difference from cells primed with C3H.SW CD11c+ DCs or medium alone (Student t test).
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the interesting possibility that such residual host APCs
could be important for amplifying GVHD response during the effector phase, perhaps in the host target tissues.
Further studies are necessary for dissecting the role of
distinct APCs in regulating these early versus later events
in the induction of acute GVHD.
The findings of this study further extend our previous observation at a cellular mechanism level that host
APCs are essential for allogeneic CD8 T cells to induce
acute GVHD in an miHA-mismatched mouse model
(12). After rapid priming for as little as 24 hours by host
DCs, allogeneic CD8+ T cells became committed to differentiation into functional effectors mediating acute
GVHD. This suggests that a blockade of DC–T cell
interaction should be required for only a short period
after BMT, until host DCs have disappeared. Despite
the phenotypic manifestation of GVHD in the second
week after BMT and beyond, it is the first few days after
BMT in which GVHD is initiated. It is this period that
should be targeted in order to ameliorate, and hopefully prevent, the subsequent development of GVHD.
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